[Federal Register Volume 78, Number 107 (Tuesday, June 4, 2013)]
[Notices]
[Pages 33443-33444]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-13226]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Norac, Inc.

    By Notice dated November 19, 2012, and published in the Federal 
Register on November 27, 2012, 77 FR 70825, Norac, Inc., DBA: Norac 
Pharma, 405 S. Motor Avenue, Azusa, California 91702-3232, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Tetrahydrocannabinols (7370)...............  I
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Nabilone (7379)............................  II
------------------------------------------------------------------------

    With regard to Gamma Hydroxybutyric Acid (2010), 
Tetrahydrocannabinols (7370), and Methamphetamine (1105) only, the 
company manufactures these controlled substances in bulk solely for 
domestic distribution within the United States to customers engaged in 
dosage-form manufacturing.
    With regard to Nabilone (7379) only, the company presently 
manufactures a small amount of this controlled substance in bulk solely 
to conduct manufacturing internal process development. It is the 
company's intention once the manufacturing process is refined to the 
point that its Nabilone bulk product is available for commercial use, 
the company will export the controlled substance in bulk solely to 
customers engaged in dosage-form manufacturing outside the United 
States. The company is aware of the requirement to obtain a DEA 
registration as an exporter to conduct this activity.

[[Page 33444]]

    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. Sec.  823(a) and determined that the 
registration of Norac, Inc., DBA: Norac Pharma, to manufacture the 
listed basic classes of controlled substances is consistent with the 
public interest at this time. DEA has investigated Norac, Inc., DBA: 
Norac Pharma, to ensure that the company's registration is consistent 
with the public interest. The investigation has included inspection and 
testing of the company's physical security systems, verification of the 
company's compliance with state and local laws, and a review of the 
company's background and history. Therefore, pursuant to 21 U.S.C. 
Sec.  823(a), and in accordance with 21 CFR Sec.  1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic classes of controlled substances listed.

    Dated: May 24, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-13226 Filed 6-3-13; 8:45 am]
BILLING CODE 4410-09-P